Human epidermoid carcinoma cells (A431) over-expressing EGFR.
Conjugate
Functional Grade
Images
Functional assay.
(A) Proliferation of BT474 cells in the presence of trastuzumab. Cells were treated with trastuzumab and cell number was measured by cell counting experiments. (B)?Response of BT474 and their trastuzumab-resistant and hypersensitive models to trastuzumab assessed in dose-response experiments by cell counting.
Tumor growth inhibition SKBR3 cells were incubated with titrations of trastuzumab (e) or enavatuzumab with cross-linking secondary antibody (f) in the presence or absence of a single concentration of the other antibody.
When antigen is immobilized at 2μg/mL (100 μL/well), the concentration for 50% of maximal effect(EC50) of this product is 0.00526 ug/ml.
Functional assay.
(A) Proliferation of BT474 cells in the presence of trastuzumab. Cells were treated with trastuzumab and cell number was measured by cell counting experiments. (B)?Response of BT474 and their trastuzumab-resistant and hypersensitive models to trastuzumab assessed in dose-response experiments by cell counting.
Tumor growth inhibition SKBR3 cells were incubated with titrations of trastuzumab (e) or enavatuzumab with cross-linking secondary antibody (f) in the presence or absence of a single concentration of the other antibody.
When antigen is immobilized at 2μg/mL (100 μL/well), the concentration for 50% of maximal effect(EC50) of this product is 0.00526 ug/ml.
My Review for Human Anti-Human HER2 (Trastuzumab) Monoclonal Antibody, clone 4D5-8 [Biosimilar]
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.